Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment

A. Shafqat, Lawrence Einhorn, Nasser Hanna, G. W. Sledge, A. Hanna, B. E. Juliar, Patrick Monahan, S. Bhatia

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: To understand the pathogenesis of fatigue in cancer, we conducted a cross-sectional study using Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-Fatigue (FACT-F) instruments to measure fatigue and assessed laboratory studies. Patients and methods: 174 patients with cancer, who had undergone treatment within the last six months, answered the questionnaires and the Brief Version Zung Self-Rating Depression Scale (BZSDS). Blood samples were drawn for hemoglobin, albumin, thyroid stimulating hormone (TSH), dehydroepiandrosterone-sulfate (DHEAS) and tumor necrosis factor-alpha (TNF- alpha). Testosterone levels were checked in male patients. Results: Clinically significant fatigue with BFI ≥4 was present in 52.0% of patients. Measurement of laboratory parameters revealed the following: DHEAS levels <80 mcg/dl in males and <36 mcg/dl in females=54.1%; BZSDS scores ≥27=20.1%; testosterone levels <200 ng/dl=26.4% of male patients. Significant correlations were noted between BFI and FACT-F, albumin levels, hemoglobin levels and BZSDS scores. In addition, for male patients BFI correlated with DHEAS and testosterone levels. In multiple linear regression, hemoglobin, BZSDS scores and current opioid use were associated with response BFI. For male patients, DHEAS <80 mcg/dl, increased BZSDS and testosterone <200 ng/dl were associated with increased BFI. Conclusion: Fatigue is common in this population and BFI correlates with more extensive measurements. Abnormalities such as decreased testosterone and DHEAS may lead to interventions that can be therapeutically exploited.

Original languageEnglish
Pages (from-to)1545-1550
Number of pages6
JournalAnnals of Oncology
Volume16
Issue number9
DOIs
StatePublished - Sep 2005

Fingerprint

Fatigue
Dehydroepiandrosterone Sulfate
Neoplasms
Equipment and Supplies
Testosterone
Therapeutics
Hemoglobins
Albumins
Thyrotropin
Opioid Analgesics
Linear Models
Tumor Necrosis Factor-alpha
Cross-Sectional Studies

Keywords

  • Cancer
  • Dehydroepiandrosterone
  • Fatigue
  • Testosterone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. / Shafqat, A.; Einhorn, Lawrence; Hanna, Nasser; Sledge, G. W.; Hanna, A.; Juliar, B. E.; Monahan, Patrick; Bhatia, S.

In: Annals of Oncology, Vol. 16, No. 9, 09.2005, p. 1545-1550.

Research output: Contribution to journalArticle

Shafqat, A. ; Einhorn, Lawrence ; Hanna, Nasser ; Sledge, G. W. ; Hanna, A. ; Juliar, B. E. ; Monahan, Patrick ; Bhatia, S. / Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. In: Annals of Oncology. 2005 ; Vol. 16, No. 9. pp. 1545-1550.
@article{ca5c63e7a51c49dabffb313503fff819,
title = "Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment",
abstract = "Background: To understand the pathogenesis of fatigue in cancer, we conducted a cross-sectional study using Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-Fatigue (FACT-F) instruments to measure fatigue and assessed laboratory studies. Patients and methods: 174 patients with cancer, who had undergone treatment within the last six months, answered the questionnaires and the Brief Version Zung Self-Rating Depression Scale (BZSDS). Blood samples were drawn for hemoglobin, albumin, thyroid stimulating hormone (TSH), dehydroepiandrosterone-sulfate (DHEAS) and tumor necrosis factor-alpha (TNF- alpha). Testosterone levels were checked in male patients. Results: Clinically significant fatigue with BFI ≥4 was present in 52.0{\%} of patients. Measurement of laboratory parameters revealed the following: DHEAS levels <80 mcg/dl in males and <36 mcg/dl in females=54.1{\%}; BZSDS scores ≥27=20.1{\%}; testosterone levels <200 ng/dl=26.4{\%} of male patients. Significant correlations were noted between BFI and FACT-F, albumin levels, hemoglobin levels and BZSDS scores. In addition, for male patients BFI correlated with DHEAS and testosterone levels. In multiple linear regression, hemoglobin, BZSDS scores and current opioid use were associated with response BFI. For male patients, DHEAS <80 mcg/dl, increased BZSDS and testosterone <200 ng/dl were associated with increased BFI. Conclusion: Fatigue is common in this population and BFI correlates with more extensive measurements. Abnormalities such as decreased testosterone and DHEAS may lead to interventions that can be therapeutically exploited.",
keywords = "Cancer, Dehydroepiandrosterone, Fatigue, Testosterone",
author = "A. Shafqat and Lawrence Einhorn and Nasser Hanna and Sledge, {G. W.} and A. Hanna and Juliar, {B. E.} and Patrick Monahan and S. Bhatia",
year = "2005",
month = "9",
doi = "10.1093/annonc/mdi267",
language = "English",
volume = "16",
pages = "1545--1550",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment

AU - Shafqat, A.

AU - Einhorn, Lawrence

AU - Hanna, Nasser

AU - Sledge, G. W.

AU - Hanna, A.

AU - Juliar, B. E.

AU - Monahan, Patrick

AU - Bhatia, S.

PY - 2005/9

Y1 - 2005/9

N2 - Background: To understand the pathogenesis of fatigue in cancer, we conducted a cross-sectional study using Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-Fatigue (FACT-F) instruments to measure fatigue and assessed laboratory studies. Patients and methods: 174 patients with cancer, who had undergone treatment within the last six months, answered the questionnaires and the Brief Version Zung Self-Rating Depression Scale (BZSDS). Blood samples were drawn for hemoglobin, albumin, thyroid stimulating hormone (TSH), dehydroepiandrosterone-sulfate (DHEAS) and tumor necrosis factor-alpha (TNF- alpha). Testosterone levels were checked in male patients. Results: Clinically significant fatigue with BFI ≥4 was present in 52.0% of patients. Measurement of laboratory parameters revealed the following: DHEAS levels <80 mcg/dl in males and <36 mcg/dl in females=54.1%; BZSDS scores ≥27=20.1%; testosterone levels <200 ng/dl=26.4% of male patients. Significant correlations were noted between BFI and FACT-F, albumin levels, hemoglobin levels and BZSDS scores. In addition, for male patients BFI correlated with DHEAS and testosterone levels. In multiple linear regression, hemoglobin, BZSDS scores and current opioid use were associated with response BFI. For male patients, DHEAS <80 mcg/dl, increased BZSDS and testosterone <200 ng/dl were associated with increased BFI. Conclusion: Fatigue is common in this population and BFI correlates with more extensive measurements. Abnormalities such as decreased testosterone and DHEAS may lead to interventions that can be therapeutically exploited.

AB - Background: To understand the pathogenesis of fatigue in cancer, we conducted a cross-sectional study using Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-Fatigue (FACT-F) instruments to measure fatigue and assessed laboratory studies. Patients and methods: 174 patients with cancer, who had undergone treatment within the last six months, answered the questionnaires and the Brief Version Zung Self-Rating Depression Scale (BZSDS). Blood samples were drawn for hemoglobin, albumin, thyroid stimulating hormone (TSH), dehydroepiandrosterone-sulfate (DHEAS) and tumor necrosis factor-alpha (TNF- alpha). Testosterone levels were checked in male patients. Results: Clinically significant fatigue with BFI ≥4 was present in 52.0% of patients. Measurement of laboratory parameters revealed the following: DHEAS levels <80 mcg/dl in males and <36 mcg/dl in females=54.1%; BZSDS scores ≥27=20.1%; testosterone levels <200 ng/dl=26.4% of male patients. Significant correlations were noted between BFI and FACT-F, albumin levels, hemoglobin levels and BZSDS scores. In addition, for male patients BFI correlated with DHEAS and testosterone levels. In multiple linear regression, hemoglobin, BZSDS scores and current opioid use were associated with response BFI. For male patients, DHEAS <80 mcg/dl, increased BZSDS and testosterone <200 ng/dl were associated with increased BFI. Conclusion: Fatigue is common in this population and BFI correlates with more extensive measurements. Abnormalities such as decreased testosterone and DHEAS may lead to interventions that can be therapeutically exploited.

KW - Cancer

KW - Dehydroepiandrosterone

KW - Fatigue

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=24044462936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044462936&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi267

DO - 10.1093/annonc/mdi267

M3 - Article

VL - 16

SP - 1545

EP - 1550

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -